Independent predictors for HAQ at week 52 in multivariable analysis
| Abatacept | Tocilizumab | |||||
|---|---|---|---|---|---|---|
| Regression coefficient | Regression coefficient | |||||
| Standardised | Unstandardised | p Value | Standardised | Unstandardised | p Value | |
| Age | 0.08 | 0.23 | 0.01 | 0.85 | ||
| Sex (male) | 0.18 | 0.45 | 0.01 | 0.11 | 0.10 | |
| Disease duration | 0.20 | 0.00 | <0.001 | 0.25 | 0.00 | <0.001 |
| Prior use of biological agents | 0.08 | 0.19 | 0.08 | 0.23 | ||
| MTX use | −0.09 | 0.15 | −0.03 | 0.59 | ||
| CRP (at baseline) | −0.02 | 0.72 | −0.09 | 0.18 | ||
| RF titre (at baseline) | −0.05 | 0.47 | −0.08 | 0.22 | ||
| MMP-3 (at baseline) | −0.04 | 0.49 | −0.05 | 0.48 | ||
| SDAI (at baseline) | 0.07 | 0.35 | −0.09 | 0.21 | ||
| HAQ-DI (at baseline) | 0.70 | 0.76 | <0.001 | 0.64 | 0.76 | <0.001 |
Significant results are shown in bold.
CRP, C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP-3, matrix metalloproteinase 3; MTX, methotrexate; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index.